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AQUAPORIN-4 IGG AUTOIMMUNE SYNDROME
AND IMMUNOREACTIVITY ASSOCIATED WITH
THYROID CANCER
Tumor cells can express so-called onconeural anti-
gens, which are normally restricted to mature neurons
and glial cells in the CNS.1 The detection of neural-
reactive immunoglobulin G (IgG) aids the diagnosis
of paraneoplastic neurologic syndromes (PNS)1;
however, the diagnostic utility and potential pathoge-
nicity of autoantibodies vary between neurologic dis-
eases. By contrast, anti-aquaporin-4 (AQP4) IgG
from patients with neuromyelitis optica spectrum
disorder (NMOSD) is a specific biomarker for
NMOSD.2 AQP4 is the most abundant water chan-
nel in the CNS, particularly abundant on astrocytes,
forming the glia limitans of the blood–brain barrier.3
There is compelling evidence that AQP4-IgG reactiv-
ity and pathogenicity is restricted to the CNS, prob-
ably through an impaired blood–brain barrier.2,3 The
clinical features of NMOSD include inflammation of
the optic nerve, spinal cord, and specific brain areas
coinciding with sites of high AQP4 expression.2,3
Some cases of NMOSD thus far reported may reflect
a paraneoplastic immune response.4
Case report. In 2002, a 64-year-old man with no
history of CNS diseases developed sudden bilateral
vision loss and constricted visual fields. Visual
acuity was 1/36 and 6/24 in the right and left eye,
respectively. Bilateral optic disc edema, greater
in the right eye, was noted. Intraocular and
intracranial pressures were normal. The neurologic
examination, brain MRI, and CSF were normal
except for the presence of oligoclonal bands in
CSF. He did not receive any treatment. After 3
months, atrophy of the optic head and visual loss
(2/36) of the right eye was apparent; the left eye
was normal. AQP4-IgG was not determined at
disease onset. Two years before the onset of optic
neuritis, the patient had undergone surgical
thyroidectomy and radioactive iodine ablation for
an aggressive oncocytic cancer of the thyroid
(follicular type). No evidence of metastatic disease
was detected by whole-body MRI. The patient was
negative for serum antithyroglobulin antibodies
and antithyroid peroxidase antibodies.
In 2006, recurrent dyspepsia occurred. A gastros-
copy demonstrated an ulcerating jejunal tumor,
which was surgically removed and diagnosed as
adenocarcinoma. Serum AQP4-IgG, anti-Ma2/TA,
antitransglutaminase, and antinuclear antibodies
were detectable in 2010. Brain MRI was normal
and whole-body MRI remained negative for meta-
static disease. Three years later (2013), the patient
died of disseminated adenocarcinoma in the retro-
peritoneum, lymph nodes, and gastrointestinal tract.
No autopsy was performed. Potentially deleterious
germline mutations such as RET, TP53, and the
mismatch repair genes MLH1, MSH2, MSH2, and
PMS2 were investigated, but none was identified.
Immunohistochemical staining for AQP4 in
the paraffin-embedded neoplastic thyroid tissue
(3 mm) and the jejunum was performed after antigen
retrieval, with primary rabbit anti-AQP-4 antibody,
dilution 1:400 (Alomone Labs, Jerusalem, Israel),
and counterstaining with toluidine blue. Staining
of the thyroid cancer revealed high-level expression
of AQP4 in multifocal areas (figure). There was no
AQP4 expression in the neoplastic tissue from the
jejunum (not shown).
Discussion. We report the clinical and laboratory
investigations of a patient with NMOSD who devel-
oped 2 apparently unrelated malignancies over
a 6-year period. AQP4 was expressed in thyroid
neoplastic tissue and later AQP4-IgG was
detectable in serum. These findings suggest that
autoimmunity against tumor-expressed AQP4
potentially elicited development of NMOSD,
extending the spectrum of paraneoplastic AQP4
autoimmunity.4 Reportedly, 5% of patients with
AQP4-IgG seropositive NMOSD had a history of
neoplastic disease.4 Furthermore, 27% of individuals
undergoing investigation for PNS were found to have
detectable AQP4-IgG.4 Congruent with the current
case, high AQP4 antigen expression in neoplastic
tumor cells has been demonstrated in PNS.5 Outside
the CNS, AQP4 is normally expressed at low levels in
basolateral plasma membranes of epithelia in a number
of tissues.2,6 It has been suggested that the differential
expression of AQP4may reflect the biological nature of
neoplastic thyroid cells.6 In this case, the thyroid tumor
was characterized as oncocytic carcinoma with high
Neurology.org/nn © 2016 American Academy of Neurology 1
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
expression of AQP4, which appeared in a multifocal
pattern (figure).
In addition to serum AQP4 IgG positivity, anti-
Ma2/TA was also detected. This antibody is viewed
as an indicator of limbic encephalitis, of which the
patient did not manifest suggestive symptoms. How-
ever, onconeural antibodies may be detected in indi-
viduals without neurologic symptoms.7 Seropositivity
for AQP4-IgG 8 years after onset of optic neuritis
suggests that the patient’s blood–brain barrier re-
mained intact, thus restricting entry of these antibod-
ies into the CNS.
This case of NMOSD with AQP4-IgG seroposi-
tivity in the context of thyroid cancer expressing
high-level AQP4 expands the spectrum of paraneo-
plastic autoimmunity targeting this antigen.
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Figure Paraneoplastic neuromyelitis optica spectrum disorder associated with anti-aquaporin-4 (AQP4)
immunoreactivity in an oncocytic thyroid carcinoma
Micrographs show immunohistochemistry performed on formalin-fixed paraffin-embedded sections of the follicular carci-
noma, thin-sectioned and stained for AQP4 and toluidine blue (A, C, D). (A) A sharp border between the neoplastic thyroid
tissue (left) and normal thyroid tissue parenchyma (right); (B) (insert) shows negative control. (C) Multifocal high-level expres-
sion of AQP4 in the neoplastic thyroid cells, which is distinctly different from the normal thyroid tissue. (D) Magnified view of
B shows AQP4 immunoreactivity predominately in the cell membrane (arrowheads). Scale bars5 200 mm (A, B), 100 mm (C),
20 mm (D).
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